Myriad Genetics reported $-17800000 in Operating Profit for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Accelerate Diagnostics AXDX:US -17070000 3.82M
Becton, Dickinson and BDX:US $ 535M 117M
Bio Rad Laboratories BIO:US $ 120.22M 23.21M
Biocept BIOC:US $ -2.71M 0.07M
Bruker BRKR:US $ 73.9M 22.6M
Danaher DHR:US $ 2205M 33M
Exact Sciences EXAS:US $ -159.58M 17.4M
Hologic HOLX:US $ 263.9M 330.2M
Illumina ILMN:US $ -579000000 763M
Johnson & Johnson JNJ:US $ 5840M 22M
Mettler Toledo International MTD:US 256.69M 43.69M
Myriad Genetics MYGN:US $ -17.8M 7.8M
Nanostring Technologies NSTG:US $ -37.09M 0.38M
Pacific Biosciences Of California PACB:US $ -67.97M 9.55M
Perkinelmer PKI:US $ 250.86M 3.99M
Quest Diagnostics DGX:US $ 388M 125M
Repligen RGEN:US $ 63.17M 3.17M
Thermo Fisher Scientific TMO:US $ 2001M 820M
Veracyte VCYT:US $ -10.73M 4.51M
Waters WAT:US $ 199.63M 4.16M